

# Toronto Cancer Hospital

Division of Tumor  
Sequencing and  
Diagnostics

123 Main St. West,  
Toronto, ON, A4B5G9

info@och.on.ca  
fax: 416-456-7890  
phone: 437-416-6470

## Draft MOLECULAR GENETICS LABORATORY RESULTS

### Patient Info:

Name:  
DOB:  
Sex:

### Patient Information:

Physician Name:  
Health Card:  
MRN #:  
Clinic: North York General Hospi-  
tal (Toronto)

Procedure Date  
2022-06-13 07:27:00

Accession Date  
2022-06-14 09:10:52

Report Date  
2022-06-15 18:14:55

### Report Details

Genome Reference - GRCh38  
Sequencing Range - Targeted variant testing, Fusion analysis

Referral Reason - Research

Analysis Location - Kingston Health Sciences Centre (Kingston)

## Table of findings:

Gene	Information	Interpretation
FLT1	30 c.1467C>G p.Ser489= heterozy- gous	Variant of uncertain clinical significance

**Summary:** One variant of uncertain clinical significance detected.. The de-  
tails regarding the specific mutations are included below.

# Toronto Cancer Hospital

Division of Tumor  
Sequencing and  
Diagnostics

123 Main St. West,  
Toronto, ON, A4B5G9

info@och.on.ca  
fax: 416-456-7890  
phone: 437-416-6470

## Variant Interpretation:

The interpretation of these variants is as follows: One variant of uncertain clinical significance was detected in the sample.

### Variant 1 of 1

Gene	Variant	Amino	Zygoty
FLT1	c.1467C>G	p.Ser489=	heterozygous

### Variant of uncertain clinical significance

The g.28301812C>G variant occurs in chromosome chr13, within the FLT1 gene, and it causes c.1467C>G change at position 489 in exon 30, forming p.Ser489=. This mutation has been identified in 40 families. It has a population frequency of 1.07e-05 (6 alleles in 561276 total alleles tested), indicating it is a very rare variant in the general population. causes no amino acid change. ClinVar and other genomic databases report the FLT1 c.1467C>G variant as clinically relevant based on aggregated evidence.

The clinical implications of this variant are not yet fully understood. At present, available data is insufficient to confirm its role in disease.

The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint.

This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV007792041).

Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 675412885, 621104844, 238198064.

# Toronto Cancer Hospital

Division of Tumor  
Sequencing and  
Diagnostics

123 Main St. West,  
Toronto, ON, A4B5G9

info@och.on.ca  
fax: 416-456-7890  
phone: 437-416-6470

According to ClinVar, the evidence collected to date is insufficient to firmly establish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance.

## Test Details:

**Genes Analyzed:** PIK3R2, total. RNF213, total. ELF4, total. PRLR, total. NRP1, total. FN1, total. ACVR1B, total. SYNGAP1, total. POT1, total. ATIC, total. FLT1, total. CDKN1B, total. BCL11B, total. 13 total genes tested.

**mRNA ref sequences tested NM\_...:** NM\_005027.4 NM\_001256071.3 NM\_001421.4 NM\_000949.7 NM\_003873.7 NM\_212482.4 NM\_004302.5 NM\_006772.3 NM\_015450.3 NM\_004044.7 NM\_002019.4 NM\_004064.5 NM\_138576.4

## Recommendations

A precision oncology approach is advised. These mutations are known oncogenic drivers, linked to constitutive pathway activation. Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment. PI3K inhibitors could be explored in trials for PIK3CA-mutated cases. Germline testing is not indicated, as all mutations are consistent with somatic events. A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discretion.

## Methodology

Total RNA was sequenced with Targeted variant testing and was analyzed using Fusion analysis covering all coding exons and adjacent intronic regions. Target enrichment was performed with hybrid capture (Twist Bioscience), followed by Illumina NextSeq sequencing. Reads were aligned to GRCh37 using BWA-MEM, and variants called with GATK. Annotation was performed in VarSeq using population databases, predictive algorithms, and ClinVar. CNVs were assessed with CNVkit and confirmed by MLPA when applicable. Regions with pseudogene interference, such as PMS2, were validated using long-range PCR and Sanger sequencing. Mean read depth exceeded 300x, with a minimum threshold of 50x. Analytical sensitivity is >99% for SNVs/indels and >95% for exon-level CNVs. **Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported**, per ACMG/AMP guidelines (PMID: 25741868).

## Limitations

This test was developed and validated in a certified clinical laboratory. Limitations include reduced sensitivity in pseudogene regions (e.g., PMS2, CHEK2), and inability to detect certain structural variants (e.g., MSH2 inversions), deep intronic changes, or low-level mosaicism. PMS2 exons 11–15 are not analyzed. Interpretations reflect current knowledge and may be updated as new evidence emerges.

## Toronto Cancer Hospital

Division of Tumor  
Sequencing and  
Diagnostics

123 Main St. West,  
Toronto, ON, A4B5G9

info@och.on.ca  
fax: 416-456-7890  
phone: 437-416-6470

Report Electronically Verified and Signed  
by:

Mock specimen